420 with CNW — New Certification Will Help Standardize Marijuana Product Testing by Labs

States that have legalized the commercial production and sale of marijuana are required to have their products tested for THC levels and contaminants. THC is one of the main psychoactive compounds in marijuana, with the other being cannabidiol (CBD). Unlike CBD, however, THC induces a high when ingested.

Industry standards for such tests aren’t well-established, a situation that allows some laboratories to inflate levels of THC in an effort to meet client needs. Last week, two marijuana testing labs launched a new program to standardize procedures for testing the potency and purity of cannabis products.

For some time now, SC Labs and ACT Laboratories have assessed lab regulatory standards across states that have legalized marijuana to develop stringent and sensible quality standards. The new program, Trust in Testing, is a collaborative and transparent project by the two companies that will give consumers confidence that they are buying high-quality products.

A 2019 survey observed inconsistencies in reports from different laboratories, with the marijuana industry also seeing scandals such as cannabis products being cleared for sale by laboratories, despite the presence of contaminants such as mold.

In a statement, SC Labs CEO Jeff Journey stated that the identification of high-quality compliant laboratories would help decentralize decision-making. The company has licensed operations in Michigan, California, Colorado and Oregon. Journey believes that the new program will afford brands a way to identify laboratories that meet the set standards across different states.

ACT Laboratories CEO Michael Drozd then explained that, with testing fraud allegations increasing in the country, it was even more important for marijuana brands to test their products in order to ensure they were all safe and reliable. He added that poor quality testing data could affect brand reputation, resulting in fines, loss of business and legal action.

The Trust in Testing certification will also enable brands to establish their own standards when it comes to choosing a testing facility. The standards introduced include regular and more proficiency testing, internal employee ethics and training programs, and the use of advanced quality management systems, among other requirements. The certification has been designed to ensure that laboratories comply with state regulations while also affording their clients and consumers reliable and accurate results.

In addition, brands that use a lab certified by Trust in Testing for their products will be allowed to use the program’s seal on their packages. This will show consumers their commitment to quality.

ACT Laboratories and SC Labs are proud to be working together to create safer marijuana through a more reliable testing landscape in the country.

For companies such as IGC Pharma Inc. (NYSE American: IGC), which want their formulations to be approved by the FDA, no concerns about testing controversies exist because the FDA process is clear and companies must take their products through the stringent clinical development process.

NOTE TO INVESTORS: The latest news and updates relating to IGC Pharma Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Missouri Sees Uptick in Marijuana Jobs Shortly After Legalization Ballot

Despite its relative youth, America’s nascent cannabis industry has been one of the most prolific job creators in the country. As of January 2022, more than 420,000 people nationwide had full-time jobs in the state-legal cannabis industry. The industry has been among the fastest-growing sectors in the country in recent years, and it is predicted to be worth $47.5 billion by 2030 as more states launch their own markets and sales pick up.

Missouri, a traditionally conservative state, is enjoying some of the labor benefits of cannabis reform after it recently approved recreational cannabis sales. Only a few months after Missouri voters approved an adult-use cannabis measure at the November ballot, thousands of residents are already earning a living from the marijuana industry.

State officials began approving retail cannabis licenses for dispensaries in early January, and the first businesses met significant product demand from customers. Less than a month after the first licenses were approved, close to 200 dispensaries had sold around $103 million worth of cannabis products, with the majority (about $72 million) coming from recreational cannabis.

Individuals who want to work in Missouri’s cannabis industry have to secure agent ID badges from the state. The state Department of Health and Human Sciences says it approved 12,970 agent ID badges by the end of February. With the market in its infancy, experts predict that the job growth within Missouri’s cannabis industry will only go up.

Se7en Staffing & Employment Solutions CEO Christy Essex says that her company has noted an increase in labor needs across the industry that still hasn’t been met. Dispensaries are having trouble keeping their shelves filled, she said, and some companies are hiring temporary employees to cover short-term labor shortfalls.

Sloane Barbour, the CEO of cannabis technology company engin, says that Missouri’s impressive performance in its first month has made it a standout in America’s state-legal cannabis space. Cannabis is posed to become a multibillion dollar industry, and she believes Missouri has the potential to compete with juggernauts such as Massachusetts and Illinois. She noted that states with billion-dollar markets, including Illinois, Massachusetts and Michigan, often employ around 30,000 to 50,000 employees in the marijuana industries.

As such, Barbour said, Missouri’s cannabis market still has plenty of potential for job growth, especially in the short-term as businesses begin hiring aggressively. This hiring spree may be slowed down if lawmakers advance a bill that would include fingerprinting as part of the background checks required before receiving an agent ID badge.

No such extensive procedures may be required if marijuana products intended for medical use were approved by the FDA in the way that companies such as IGC Pharma Inc. (NYSE American: IGC) hope for. These companies are working to see chronic pain formulations from cannabis be approved as mainstream medicines.

NOTE TO INVESTORS: The latest news and updates relating to IGC Pharma Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Bipartisan Bill Before Congress Seeks to Force DEA to Allow Patient Use of Cannabis, Psychedelics

A bipartisan group of congressional lawmakers has filed a measure that would compel the U.S. Drug Enforcement Administration (DEA) to allow seriously ill patients to use psychedelics and cannabis. The bill would clarify that gravely ill individuals have the right to access alternative treatments under federal Right to Try (RTT) laws that allow them to use schedule 1 drugs if they don’t get any relief from traditional treatments.

An RTT policy signed into law by President Donald Trump when he was still in office already grants terminally ill patients access to investigational drugs that have gone through clinical trials, even if they are classified in schedule 1 of the Controlled Substances Act. However, the DEA refused to allow a Seattle physician to offer psilocybin therapy under RTT laws to patients with terminal conditions in 2021, forcing the doctor to file a series of lawsuits against the agency to compel it to grant psychedelic access to end-of-life patients.

The recent bill would amend existing law to clarify that despite the DEA’s move to reject psilocybin access under RTT laws, end-of-life patients should be able to use such treatments. The Right to Try Clarification Act was introduced by Representatives Nancy Mare and Earl Blumenauer and cosponsored by Representatives Andy Biggs, Lou Correa and Madeline Dean.

Led by Senators Rand Paul and Cory Booker and Representatives Early Blumenauer and Nancy Mae, a prior version of the bill was introduced in Congress last year, but it failed to advance.

Blumenauer said that patients with terminal illnesses have the right to discuss treatments such as psilocybin that could provide long-term relief from symptoms such as anxiety, depression and pain. He noted that such patients had been prevented from accessing beneficial treatments due to federal restrictions for too long and that the proposed bill would finally allow these individuals to try alternative treatments that could provide sustained relief regardless of the classification of the treatments on the Controlled Substances Act.

Forty-one states have Right to Try laws that allow terminally ill patients to access treatments in investigational stages, including psilocybin, Blumenauer said. He added that MDMA and psilocybin have exhibited much medical potential in early clinical trials. Despite this, Blumeauer continued, the DEA has “refused to accommodate” RTT laws and denied end-of-life patients the right to choose their preferred treatments.

If his bill succeeds, it could impact the ongoing case that has seen the DEA field lawsuits from a physician and patients trying to access psilocybin therapy.

Meanwhile, a number of companies, including IGC Pharma Inc. (NYSE American: IGC), are investing millions of dollars into developing therapeutic formulations from cannabis. These formulations could get approved by the FDA if the development process proceeds as the startups hope they will.

NOTE TO INVESTORS: The latest news and updates relating to IGC Pharma Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Germany to Proceed with Toned-Down Marijuana Legalization Plan as EU Review Awaits

Officials in Germany intend to move forward with a toned-down version of cannabis legalization after abandoning — at least temporarily — a more comprehensive proposal that would have brought about legal cannabis sales throughout the nation. Karl Lauterbach, the nation’s health minister, had promised to introduce new marijuana regulations by the end of March this year.

The new model, which consists of two parts, was first reported by Zeit and aims to legalize cannabis countrywide without breaking EU regulations. The model will, for four years, permit restricted cannabis sales in some areas, much like a pilot program. In doing so, officials would be able to observe how reforms were being implemented in both urban centers and more rural areas. The program can then be expanded to other regions of the nation if it is deemed successful.

Lauterbach’s plan would also permit Germans to cultivate marijuana for personal use. While the latter part of the plan would require review by the EU Commission, the former would not, according to reports.

Although specifics of the homegrow rules have not been decided, reports indicate that the proposal would permit consumers to own up to 30 marijuana plants. Additionally, independent cultivators can distribute the produce among themselves via “marijuana clubs.” These clubs are already legal in Spain and the Netherlands.

Last year, government representatives from the Netherlands, Germany, Luxembourg and Malta met to talk about legalizing marijuana. Moreover, the country’s federal cabinet approved a preliminary outline for a legalization bill at the end of last year, but the government wanted European Union approval to make sure that enacting the legislation wouldn’t violate international obligations.

Under that preliminary framework, persons older than 18 years of age would have legal access to possess up to 30 grams of cannabis, which could be bought from establishments with federal licenses. Eligible persons could also cultivate up to three marijuana plants for their own use, subject to restrictions on enclosure to keep minors out.

The plan calls for a special consumption tax in addition to the nation’s sales tax being applied to marijuana. And after the reform is put into effect, all ongoing criminal cases involving offenses that are now legal will be halted.

Earlier this month, Lauterbach stated that officials would be revising the proposal before introducing a bill in parliament as they had received “positive feedback” from the EU The framework was the result of several months of analysis and discussion between the German government and the nation’s coalition government. A series of hearings intended to inform legislation to end the nation’s prohibition were launched last summer by officials as a steppingstone toward legalization.

As more countries around the world take steps to end the prohibition of marijuana, many companies such as India Globalization Capital Inc. (NYSE American: IGC) are going a step further to develop medicines from compounds extracted from this plant, and these compounds are expected to gain the approval of regulators once the the clinical development process has been successfully completed.

NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Kentucky Governor Enacts Medical Cannabis Legalization Law

Only hours before the end of the 2023 session, a proposal to make medical marijuana legal in Kentucky went through the state senate on Thursday after ten years of fruitless attempts.

In front of a bipartisan group of lawmakers and supporters on Friday morning, Governor Andy Beshear enacted the legislation, putting Kentucky among the states resolving to end the prohibition of medicinal marijuana. The initiative will be active starting in early 2025.

In two of the previous three years, House Representatives had approved a medicinal marijuana measure, which was rejected at the Senate because of insufficient support from the party’s Republican caucus. The law was introduced on the floor of the Senate this year and was successfully passed through that chamber two weeks ago.

According to Senate Bill 47, the program as well as its growers, producers, and dispensaries would be subject to oversight, operation, implementation, and control by the Family Services and Health Cabinet.

In Kentucky’s approach, patients would qualify for a medical card for marijuana if they had one of at least six medical conditions; cancer of any kind, irrespective of the stage, crippling pain, seizure disorders, stiffness, persistent nausea, and PTSD are among the qualifying illnesses.

A patient may also qualify if they have a diagnosis of a sickness or health problem and the recently formed Cannabis Center decides that usage of cannabis would be beneficial. The center may decide that the individual is likely to obtain therapeutic, medical, or palliative benefits based on research and evidence.

Individuals getting medical marijuana from a dispensary will be able to ingest it through edible items and topical applications rather than smoking it.

Representative Jason Nemes, a proponent who previously served as the primary sponsor of medicinal cannabis legislation, cautioned the committee that, through the proposed bill, patients who choose to smoke cannabis rather than consume it in other ways would be in violation of the law and may potentially lose their medicinal marijuana cards.

Representative Matt Lockett, one of the bill’s critics, argued that since the law won’t be in practice until 2025, there is still time for it to be improved and passed the following year. Opposers of the bill claimed that there aren’t enough studies demonstrating the effectiveness and security of using cannabis as medical care.

Republican lawmakers celebrated the historic significance of the occasion at the signing function on Friday morning in Rotunda. They also celebrated the reality that thousands of people who are suffering will receive assistance.

While Kentucky is celebrating the enactment of a medical marijuana law, residents can also take additional comfort from the knowledge that there are companies like India Globalization Capital Inc. (NYSE American: IGC) that are working tirelessly to develop pharmaceutical-grade medicines from a number of cannabis compounds for the treatment of ailments like chronic pain.

NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW – Delaware Senate Passes Cannabis Legalization Bills, Sends to Governor

Last Tuesday, the Senate in Delaware gave its nod of approval to a pair of proposals earlier voted through by the House that seek to legalize possession of cannabis and establish market regulations for the recreational consumption of cannabis. These bills will now be forwarded to the state’s governor.

The regulation proposal sailed through on a 15 to 5 vote tally, while the simple legalization proposal garnered a 16 to 4 tally in the chamber. Representative Ed Osienski sponsored both bills, which snaked their way through several legislative panels before getting a floor vote.

The sponsor made use of a similar, stratified approach for the legislation during the prior session, which resulted in the fundamental legalization draft being approved while the regulation version was narrowly defeated.

According to HB 1 as well as HB 2, the state laws would change to allow individuals over the age of 21 to have, share, use or buy as much as one ounce of marijuana. The measure stipulates that “independent person sharing” doesn’t entail distributing cannabis simultaneously with another reciprocating exchange involving the respective persons, such as exchanging a noncannabis item, to prevent abuse of the “gift-giving” provision. Marijuana cultivation as well as public use would remain illegal. Civil fines not exceeding $100 may be levied on under-aged individuals who engage in the banned behavior if it is their first violation. However, the police is at liberty to exercise restraint and impose a citation in lieu of a fine.

The measure offers a foundational framework for putting in place a controlled cannabis business system for recreational marijuana in the jurisdiction. Under the creation of the newly formed Office of the Commissioner for Marijuana Control, the Tobacco and Alcohol Enforcement Department (DATE) will be charged with overseeing the regulation of the market.

A maximum of 30 commercial cannabis permits may be issued by regulators after just 16 months of the market launching.

The scoring procedure before license issuance will give priority to candidates who demonstrate a capacity to offer a decent salary, health insurance, paid time off for illness and an emphasis on hiring a diverse pool of candidates.

A Fund for Justice Reinvestment that promotes transitional justice, job placement, technical support for the financially disadvantaged as well as similar initiatives would receive 7% of cannabis business fees.

Before this decision on Bill 2, members opposed two amendments proposed by the GOP. One intended to alter the Cannabis Regulation Commission’s organizational structure while also enabling those facing penalties, cancellation of licenses or license termination to request regulators to furnish them with the pertinent records backing such actions. This alternative bill could have removed any language referring to the necessity of marijuana companies to signing labor/employee peace agreements.

Marijuana legalization is sweeping across the country, and its growing popularity is aided by the R&D work being undertaken by enterprises such as India Globalization Capital Inc. (NYSE American: IGC), which hope to commercialize a number of medicinal formulations from different cannabinoids, such as THC.

NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Australian Study Reveals Spike in Medical Marijuana Use

A recent study by Australian researchers has revealed a dramatic increase in the number of Australians using medical cannabis. Researchers from the Lambert Initiative at the University of Sydney found that even though most Australians still use illicit cannabis as a therapeutic alternative, medical marijuana prescriptions have risen significantly.

The Cannabis as Medicine Survey (CAMS20) quizzed 1,600 Australians on their medical cannabis use from September 2020 to January 2021. Its findings were published in the “Harm Reduction Journal.”

The poll found that 37% of participants had received a medical cannabis prescription within the survey period compared to the 2.5% of respondents who had medical cannabis prescriptions during the prior Cannabis as Medicine Survey (CAMS18), which ran from 2018–2019.

Nicholas Lintzeris, president of the Chapter of Addiction Medicine in the Royal Australasian College of Physicians as well as conjoint professor in the department of Addiction Medicine at the University of Sydney and lead researcher, said that the data suggests customers are shifting from illicit cannabis to the legal medical marijuana market.

Australia legalized medical cannabis in February 2016 when the Narcotic Drugs Act was amended to allow the cultivation of cannabis for scientific and medical purposes. Lintzeris noted that transitioning to the legal market has benefits, such as granting Australians access to safer means of consuming cannabis. He also noted that people purchasing from the illicit market are more likely to smoke cannabis (44%) compared to medical marijuana patients who can use vaporized or oral cannabis products (22% and 72%, respectively). Furthermore, most respondents (95%) reported improved health after switching to medical cannabis.

The survey also reported that 52% of the respondents said they used prescribed medical cannabis for pain, 26% to address mental health issues, and 6% to alleviate insomnia. On the other hand, 40% of the respondents used illicit cannabis for pain, 31% for mental health issues, and 11% to help them sleep. Respondents who used illicit cannabis reported high costs as a major barrier to entering the legal medical marijuana program; the average cost of regular medical cannabis treatments in Australia is around $79 per week. They also reported that it was difficult to find physicians willing to prescribe medical cannabis.

Despite these barriers to access, Professor Iain McGregor, academic director of the Lambert Initiative for Cannabinoid Therapeutics, said that using prescribed medical marijuana is more advantageous. On top of safer administration routes, medical marijuana patients have access to safer and more precise prescriptions, better communication with their doctors and greater certainty to access, McGregor observed.

This growing use of cannabis for medicinal purposes in Australia and around the world suggests that there may be demand for the cannabis-based medicines that companies such as India Globalization Capital Inc. (NYSE American: IGC) are developing.

NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Marijuana Firms Register Mixed Results from Foray into Twitter Adverts

Angel Ferrer, the head marketing executive of Hemper Co., created a Twitter profile and uploaded an advertisement for the company’s products on the market, stocked with a range of marijuana accessories, in February, when Twitter allowed cannabis ads. The account was deleted by Twitter shortly thereafter. Ferrer said he would keep learning how to deal with Twitter regardless of the disabling of his initial ad.

The first big digital media site to permit marijuana advertising was Twitter, which has its headquarters in San Francisco. But there are several limitations for marketers, as companies such as Hemper are discovering.

Cannabis businesses must first obtain platform approval and adhere to other guidelines, such as having a license in areas where they conduct business and limiting their customer base to individuals older than 21. Twitter forbids the advertising of drugs and drug-related items but allows businesses to advertise their products and services. Twitter has provided a six-week promotional incentive for marijuana brands to boost marijuana ad sales.

The business announced that it will meet new advertising expenditures of up to $250,000 on a single-transaction basis. The limited-time deal is valid through March 31, 2023.

Kate Lynch, the marketing vice president for Curaleaf Holdings, expressed excitement about having a new platform to advertise the business’s goods and immediately began a Twitter advertising strategy. The corporation advertised for a fortnight to see if it would drive traffic to its website. According to Lynch, the company will shortly update the advertisement with fresh content.

The company attempted to demonstrate which burned more quickly in a video advertisement that was not accepted by Twitter: a normal marijuana roll or a marijuana cigar rolled using one of the company’s products.

Additional social media companies are likely to emulate Twitter’s example, according to several industry analysts. Will cannabis businesses, however, make a profit from their expenditures? Many people assume that sites such as Google and Facebook, which are publicly accessible companies, won’t allow cannabis ads before the substance is made legal on a federal level.

Recent changes to Google’s ad network have reduced prohibitions on cannabis and cannabidiol marketing in a few countries, but a majority of other marijuana promotion is still not allowed.

While businesses such as Purple Rose and Curaleaf can track how many website clicks their Twitter advertising generated, they are unable to discern whether those clicks were translating into actual sales.

For companies such as India Globalization Capital Inc. (NYSE American: IGC), the advertising woes faced by marijuana companies aren’t an issue because companies taking their products through the FDA-approval process follow a different path to market.

NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Major Association in Alcohol Industry Backs Federal Cannabis Legalization

A major industry group representing the alcohol industry urged lawmakers to federally legalize adult-use marijuana in a letter sent to congressional leaders on Wednesday. According to the WSWA, the current disparity between federal and state law not only has negative effects on both cannabis users and nonusers, but it will also have prolonged effects on public safety and health.

In its letter, the association emphasized two major points: first, cannabis regulation could be modeled after the current alcohol system, and second, piecemeal cannabis reform is unworkable, so legislators should take a comprehensive approach to the problem.

Additionally, the letter emphasizes the need for states to maintain their independence in deciding whether or not to legalize marijuana within their territory. Moreover, it endorses the proposal for the national government to permit interstate cannabis trade, which is a view that is broadly shared by lawmakers and business leaders in the majority of states.

The WSWA cited a 2021 policy brief that outlines the regulatory priorities it believes legislators should consult as they work to find a framework for legalization. According to the policy brief, legislators should borrow experiences from alcohol regulations and guidelines to create a marijuana regulatory framework that fosters public safety, innovation and industry competition.

WSWA outlined four major guidelines for federal control over a supply chain for marijuana for adult use: the federal licensing of marijuana growers, importers, testing labs and distributors; the control and approval of marijuana products; the effective and efficient collection of excise tax at the federal level; and the effective implementation of strategies to promote public safety.

In its policy brief’s conclusion, WSWA — which in 2018 spoke out in favor of states legalizing marijuana — explained its decision to offer advice on federal marijuana reform. According to the report, a secure and prosperous market has since emerged after the end of alcohol prohibition, one that meets the requirements of consumers and regulators alike.

Cannabis regulation and legalization bills at the federal level have twice passed through the House but failed in the Senate due to the latter’s failure to pass comprehensive reform. WSWA’s involvement, according to proponents of legalization, could strengthen efforts to persuade lawmakers to take the matter more seriously.

A significant distinction between the WSWA’s proposal and that of Chuck Schumer, Senate Majority Leader, is the allocation of regulatory responsibility. Advocates have expressed concern about the Senate proposal’s deference to the FDA, and it is likely that many stakeholders would find WSWA’s position on having TTB handle basic oversight to be more agreeable.

That jostling aside, a less controversial path is being explored by various enterprises, such as India Globalization Capital Inc. (NYSE American: IGC), in which efforts are being deployed to produce FDA-approved medicines from cannabis constituents such as THC for several indications.

NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Swiss Capital to Run Pilot Program of Marijuana Legalization

In an experiment to evaluate the financial and social advantages of controlling marijuana, the Swiss regime has authorized its intentions to end the criminalization of the trade and use of marijuana in Zurich. Beginning this summer, some 2,100 Zurich residents will be allowed to purchase the medicine in predetermined amounts for individual use from drugstores, social clubs and medical facilities throughout the city.

As a requirement for the research carried out in partnership with Zurich University, those participating will respond to survey questions every six months regarding their consumption patterns and health impacts. The experiment’s ultimate goal is to ascertain the circumstances wherein Switzerland’s permission for marijuana use can be consistent with enhancing private and public wellness and safety, according to the leaders of the study.

In the following year, the evidence gathered from the experiment will be made public in bits and pieces. The goal is to gather solid real-world data that will aid in the creation of new marijuana regulations.

This decision was made at a time when other regions of Europe are reviewing their cannabis laws in reaction to broader shifts in worldwide drug laws. In the weeks to come, Germany, the continent’s largest economy, anticipates introducing a bill legalizing cannabis use and sales, making it the first European Union nation to allow for the drug’s widespread commercial sale. The Czech Republic and nearby Luxembourg also recently introduced measures to allow marijuana for adult use. Small quantities of the substance for personal use are not considered illegal in Spain, Italy and Australia.

In 2021, Malta, the smallest EU country, became the first nation in the union to legalize marijuana for personal use and to allow the creation of individual marijuana clubs where users can cultivate and exchange the drug. For the past 10 years, efforts have been made to end the prohibition of the substance in Uruguay, Canada and most recently, Thailand.

Residents of Zurich are welcome to register if they’re willing to participate in the experiment. Participants must be active marijuana users who are of consenting age, do not have any chronic medical issues, and aren’t fully engaged as commercial drivers.

Primary-care surveys indicate that roughly one-third of consenting Swiss citizens have reportedly tried marijuana. Approximately 13,000 citizens of Zurich are frequent users.

In the upcoming months, more investigations are also anticipated in Bern, Thun, Basel, Olten, Geneva, Winterthur and Biel, with support from the public and academic sectors.

While these efforts abroad are ongoing to test the waters of cannabis legalization, several companies in the United States, such as India Globalization Capital Inc. (NYSE American: IGC), are doing their own research aimed at developing a number of formulations that are effective against health conditions such as chronic pain and others.

NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.